Transgene SA (Transgene)

Oncology Corporate Profile

Company Description

Transgene, a member of the Institut M?©rieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company's four clinical-stage programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver cancer; TG4001 for oropharyngeal cancer (under a collaboration with the EORTC) and TG4040 for chronic Hepatitis C.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Pexa-Vec / JX594/TG6006oncolytic virusHepatocellular carcinoma (HCC)IIIJennerex
Pexa-Vec (+ sorafenib) / JX594/TG6006oncolytic virusHepatocellular carcinoma (HCC)IIISillajen
Pexa-Vec (+ nivolumab) / JX594/TG6006oncolytic virusHepatocellular carcinoma (HCC)II
TG4010immunotherapyNon Small Cell Lung Cancer (NSCLC)II
TG4010 (+ nivolumab)immunotherapyNon Small Cell Lung Cancer (NSCLC)IIBristol Myers-Squibb
TG4010 (+ chemotherapy)immunotherapyNon Small Cell Lung Cancer (NSCLC)IIBristol Myers-Squibb
Pexa-Vec (+ ipillmumab) / JX594/TG6006oncolytic virusVarious cancer typesII
TG6002oncolytic virusGlioblastoma Multiforme (GBM)I
Pexa-Vec / JX594/TG6006oncolytic virusVarious cancer typesIJennerex

View additional information on product candidates here »


Recent News Headlines

There are no news items to display